Dr. Reddy's Laboratories Acquires Nimbus Health GmbH

Takeda Acquires Nimbus Therapeutics' TYK2 Program Subsidiary (Nimbus Lakshmi)

February 8, 2023

Pharmaceuticals

Takeda Pharmaceutical Company Limited has completed the acquisition of all shares of Nimbus Lakshmi, Inc. (the TYK2 program subsidiary of Nimbus Therapeutics) for approximately $4.0 billion upfront, with up to $2.0 billion in potential milestone payments. The deal adds TAK-279 (NDI-034858), a selective oral TYK2 inhibitor moving into late‑stage development, strengthening Takeda's late‑stage pipeline in immune‑mediated diseases including psoriasis and other immunological indications.

Bregal Unternehmerkapital Acquires Majority Stake in medavis GmbH

September 26, 2022

Software

Bregal Unternehmerkapital has taken a majority stake in medavis GmbH, a Karlsruhe-based provider of radiology information systems (RIS) with roughly 20% market share in the DACH region. The two founders, Jörg Dittrich and Elmar Kußmaul, retained significant stakes; Bregal plans to support geographic expansion, product development and extension into adjacent healthcare IT areas.

Dr. Reddy's Acquires MenoLabs Women’s Supplement Brand from Amyris

January 5, 2024

Consumer Products

Dr. Reddy's Laboratories has acquired the MenoLabs dietary supplement portfolio and accompanying MenoLife health tracker app from Amyris as part of Amyris' Chapter 11 asset sale, winning the assets in an auction for $3.0 million. The acquisition adds seven branded menopause- and healthy-aging-focused supplements sold primarily via DTC e-commerce and marketplaces to Dr. Reddy's U.S. self-care and wellness portfolio to accelerate growth in women's nutritional and wellness markets.

Adragos Pharma Acquires Baccinex

February 6, 2025

Pharmaceuticals

Adragos Pharma, a Munich-headquartered CDMO, has acquired Baccinex, a Swiss sterile fill-finish specialist based in Courroux, Jura. The acquisition adds a US FDA- and EU-GMP-certified 6,200 m² facility and over 110 sterile fill-finish experts to Adragos' global manufacturing network, enhancing its clinical and commercial sterile manufacturing capabilities.

Novartis Acquires Regulus Therapeutics

June 25, 2025

Biotechnology

Novartis has completed the acquisition of Regulus Therapeutics, making Regulus an indirect wholly owned subsidiary following a tender offer and merger. The deal secures Regulus' investigational oligonucleotide therapy farabursen for ADPKD and strengthens Novartis' renal disease pipeline.

Lupin Healthcare Acquires Renascience Pharma Limited (UK)

April 2, 2025

Pharmaceuticals

Lupin Healthcare (UK) Limited, a wholly owned subsidiary of Lupin Limited, has acquired UK-based Renascience Pharma Limited, the sole supplier of four specialty branded products in the UK. The acquisition (reported at approximately £12.3 million) expands Lupin's branded specialty portfolio in the UK and strengthens its supply offerings to the NHS across infectious disease, ENT and cardiology/renal indications.